Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00910455 · ClinicalTrials.gov registry record · Phase 1
Study of SRX246 Capsules in Healthy Adult Volunteers
A Phase 1 study, sponsored by Azevan Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
NCT00910455: Completed Phase 1 study, sponsored by Azevan Pharmaceuticals.
NCT00910455 is a Phase 1 study that has completed, run by Azevan Pharmaceuticals. The registered enrollment target is 49 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (18% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00910455, a Phase 1 study, has completed, sponsored by Azevan Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
Study Summary
This is the first study of SRX246 in humans, and is being conducted to begin to establish a safety profile of orally administered SRX246.
Interventions
- DRUG Placebo
- DRUG SRX246
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2009-05 |
| Est. Completion | 2009-09 |
| Phase | Phase 1 |
What the finished NCT00910455 record still lists
NCT00910455 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (18% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00910455 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00910455 about?
NCT00910455 is a clinical study titled "Study of SRX246 Capsules in Healthy Adult Volunteers". This is the first study of SRX246 in humans, and is being conducted to begin to establish a safety profile of orally administered SRX246.
What is the current status of trial NCT00910455?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2009-05. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00910455?
The interventions under investigation include: Placebo (DRUG), SRX246 (DRUG).
Who is sponsoring clinical trial NCT00910455?
This trial is sponsored by Azevan Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00910455's enrollment target sits among peer trials
49 1017th of 2000 higher than 976 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia